Cointime

Cytheris

company

About

Cytheris is biopharmaceutical company focused on the R&D of therapies for immune modulation.

Highlights

Total Funding Amount
$45.70M
Funding Rounds
2
Investors
2

Details

Last Funding Type
Series D
Last Funding Money Raised
$15M
Industries
Biopharma,Biotechnology,Therapeutics
Founded date
Jan 1, 1999
Operating Status
Close

Cytheris is a privately held clinical-stage biopharmaceutical company focused on research and development of therapies for immune modulation. These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV, HCV, and HBV or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT).

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$45.70M
Cytheris has raised a total of $45.70M in funding over 2 rounds. Their latest funding was raised on Jun 7, 2010 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 7, 2010 Series D $15M 1 — — Detail
Oct 25, 2006 Series B $30.70M 2 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
2
Cytheris is funded by 2 investors. Bioam Gestion and T2C2 Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Bioam Gestion — Series D
T2C2 Capital — Series B
Cointime
İçerikler
Şirket.